Hospital
ST Lukes Medical Center LP
ST Lukes Medical Center LP was paid $23.88M by Medicaid between Jan 2018 and Oct 2024, across 224 billing codes. Its largest line is 99285, emergency room visit (most serious) — 22% of everything it billed.
33Billing provider infoST LUKES MEDICAL CENTER LP
TEMPE, AZ 85281
TEMPE, AZ 85281
33aNPI1225086028assigned 05/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.88M
24GClaims642,970
24DCodes billed224
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#25 of 78
Median peer was paid$12.21M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 93,962 | $3.66M | |
| 2019 | 90,688 | $3.62M | |
| 2020 | 78,229 | $3.17M | |
| 2021 | 107,665 | $3.63M | |
| 2022 | 116,066 | $4.08M | |
| 2023 | 93,742 | $3.37M | |
| 2024incomplete | 62,618 | $2.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 20,180 | 17,951 | $5.19M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 28,163 | 25,733 | $3.53M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 28,768 | 26,200 | $3.21M |
| 80053 | Comprehensive metabolic panel | 11% | 27,869 | 24,018 | $2.56M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.1% | 3,359 | 3,162 | $1.93M |
| 70450 | Computed tomography, head or brain; without contrast material | 7.0% | 5,507 | 5,122 | $1.67M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.1% | 3,413 | 3,220 | $1.46M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.4% | 1,566 | 1,509 | $577K |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.1% | 1,323 | 1,254 | $508K |
| 80050 | General health panel | 1.6% | 1,350 | 1,299 | $390K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.5% | 396 | 324 | $358K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 3,111 | 2,966 | $267K |
212 more codes
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.0% | 588 | $245K |
| 64483 | <1% | 410 | $229K | |
| 73562 | <1% | 1,097 | $141K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,233 | $131K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,099 | $108K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,631 | $97K |
| 70486 | <1% | 1,056 | $95K | |
| 90870 | <1% | 2,262 | $85K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 699 | $85K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,166 | $76K |
| 73130 | <1% | 853 | $75K | |
| 73610 | <1% | 762 | $59K | |
| 93458 | <1% | 68 | $57K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 14,605 | $57K |
| 95811 | <1% | 100 | $54K | |
| 73630 | <1% | 841 | $48K | |
| 93975 | <1% | 83 | $36K | |
| 72131 | <1% | 105 | $33K | |
| 73030 | <1% | 797 | $30K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,276 | $29K |
| 62321 | <1% | 90 | $29K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,625 | $28K |
| 12001 | <1% | 172 | $27K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 443 | $25K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,888 | $24K |
| 36410 | <1% | 32 | $24K | |
| G0378 | Hospital observation service, per hour | <1% | 6,008 | $19K |
| 73110 | <1% | 197 | $18K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 542 | $17K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,231 | $13K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,093 | $12K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 734 | $12K |
| C1776 | Joint device (implantable) | <1% | 30 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,746 | $11K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 26 | $11K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,616 | $10K |
| 64484 | <1% | 66 | $10K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,164 | $10K |
| 10060 | <1% | 132 | $10K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 125 | $9K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,817 | $8K |
| 99152 | <1% | 1,914 | $7K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 760 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,066 | $7K |
| 12002 | <1% | 24 | $7K | |
| 96376 | <1% | 4,406 | $6K | |
| 72100 | <1% | 67 | $6K | |
| 87186 | <1% | 2,431 | $6K | |
| 71101 | <1% | 25 | $5K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 249 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,948 | $4K |
| 73080 | <1% | 54 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 34 | $4K |
| 86901 | <1% | 1,599 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 371 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,088 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,453 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 35,045 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,651 | $3K |
| 12011 | <1% | 25 | $2K | |
| 73090 | <1% | 26 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 626 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,390 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,096 | $1K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $1K |
| 84484 | <1% | 9,134 | $1K | |
| 84703 | <1% | 6,149 | $1K | |
| 71250 | <1% | 14 | $983.32 | |
| 83690 | <1% | 11,267 | $913.73 | |
| 81003 | <1% | 8,990 | $887.96 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 43,453 | $834.79 |
| A9270 | Non-covered item or service | <1% | 5,006 | $614.65 |
| 29125 | <1% | 25 | $580.40 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,016 | $560.76 |
| 82803 | <1% | 49 | $497.35 | |
| 81025 | <1% | 7,806 | $497.00 | |
| 85730 | <1% | 5,912 | $478.46 | |
| 83605 | <1% | 3,532 | $475.76 | |
| 97597 | <1% | 15 | $423.23 | |
| 73140 | <1% | 16 | $423.08 | |
| 90715 | <1% | 1,198 | $422.44 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 16,990 | $417.61 |
| 85610 | <1% | 7,150 | $406.76 | |
| 85379 | <1% | 2,479 | $395.32 | |
| 81001 | <1% | 10,217 | $384.71 | |
| 94761 | <1% | 2,345 | $372.31 | |
| 87428 | <1% | 1,096 | $371.02 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,623 | $365.92 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 804 | $358.16 |
| 93971 | <1% | 383 | $353.86 | |
| 87400 | <1% | 1,553 | $348.77 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,402 | $347.65 |
| 87040 | <1% | 3,421 | $300.85 | |
| 82550 | <1% | 5,088 | $260.78 | |
| 87088 | <1% | 3,022 | $239.40 | |
| J3490 | Unclassified drugs | <1% | 304 | $233.60 |
| 85027 | <1% | 2,351 | $231.94 | |
| 84702 | <1% | 1,367 | $203.32 | |
| 83735 | <1% | 5,147 | $202.55 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 838 | $192.14 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 837 | $187.62 |
| 83880 | <1% | 3,055 | $179.31 | |
| 80320 | <1% | 5,327 | $165.13 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,988 | $162.09 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,278 | $161.45 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,419 | $155.93 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,180 | $142.91 |
| 87081 | <1% | 1,578 | $134.88 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 365 | $127.37 |
| 87077 | <1% | 1,296 | $118.34 | |
| 82962 | <1% | 7,072 | $117.85 | |
| 76801 | <1% | 243 | $109.78 | |
| 72040 | <1% | 28 | $103.21 | |
| 86900 | <1% | 1,599 | $94.94 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 538 | $94.50 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 59 | $91.73 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,264 | $90.22 |
| 87210 | <1% | 884 | $86.00 | |
| 80076 | <1% | 688 | $79.39 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 986 | $76.64 |
| 82077 | <1% | 1,510 | $71.68 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,166 | $71.63 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,315 | $62.33 |
| 76937 | <1% | 316 | $59.59 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,541 | $56.31 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,765 | $48.33 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,740 | $44.58 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,301 | $42.10 |
| 76830 | Ultrasound, transvaginal | <1% | 109 | $40.59 |
| 96367 | <1% | 12 | $39.37 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,092 | $38.63 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 652 | $36.62 |
| 86850 | <1% | 808 | $30.99 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 946 | $26.25 |
| 94664 | <1% | 981 | $26.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,601 | $21.76 |
| 88304 | <1% | 77 | $20.04 | |
| 85007 | <1% | 774 | $16.58 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,197 | $15.97 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,042 | $15.13 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 90 | $14.71 |
| J2704 | Injection, propofol, 10 mg | <1% | 6,004 | $12.75 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 691 | $12.54 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,244 | $11.32 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,445 | $10.35 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,257 | $9.66 |
| 82150 | <1% | 363 | $9.16 | |
| 87807 | <1% | 76 | $8.57 | |
| 87147 | <1% | 193 | $8.25 | |
| 82947 | <1% | 710 | $7.58 | |
| 87070 | <1% | 221 | $6.01 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 998 | $5.55 |
| 82271 | <1% | 13 | $3.54 | |
| 87205 | <1% | 373 | $2.77 | |
| 87420 | <1% | 144 | $2.34 | |
| 94760 | <1% | 1,055 | $2.02 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,032 | $1.74 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 933 | $1.50 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 297 | $0.68 |
| 85018 | 0% | 59 | $0.00 | |
| 80329 | 0% | 504 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 484 | $0.00 |
| 85652 | 0% | 128 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 425 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 269 | $0.00 |
| 88342 | 0% | 321 | $0.00 | |
| 82553 | 0% | 219 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 322 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 120 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 279 | $0.00 |
| 85651 | 0% | 12 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 189 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 54 | $0.00 |
| 82270 | 0% | 27 | $0.00 | |
| 84132 | 0% | 278 | $0.00 | |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 52 | $0.00 |
| C1769 | Guide wire | 0% | 41 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 18 | $0.00 |
| 74021 | 0% | 12 | $0.00 | |
| 96368 | 0% | 14 | $0.00 | |
| 97165 | 0% | 47 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 14 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 13 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 29 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 16 | $0.00 |
| 80143 | 0% | 324 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 334 | $0.00 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 0% | 103 | $0.00 |
| 85014 | 0% | 99 | $0.00 | |
| 80179 | 0% | 258 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 540 | $0.00 |
| 97161 | 0% | 167 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 663 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 48 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 265 | $0.00 |
| C9364 | Porcine implant, permacol, per square centimeter | 0% | 97 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 486 | $0.00 |
| 82272 | 0% | 40 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 96 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 48 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 48 | $0.00 |
| 85520 | 0% | 58 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 36 | $0.00 |
| 82805 | 0% | 120 | $0.00 | |
| 84600 | 0% | 18 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 24 | $0.00 |
| 97116 | 0% | 27 | $0.00 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 90 | $0.00 |
| 74018 | 0% | 54 | $0.00 | |
| A6255 | Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | 0% | 12 | $0.00 |
| 84100 | 0% | 105 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 61 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFLINN, JAMES (HOSPITAL CEO)
| Provider | Location | Paid |
|---|---|---|
| ST Lukes Medical Center LP | Phoenix, AZ | $8.69M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.